AQR Capital Management LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

AQR Capital Management LLC purchased a new position in REGENXBIO Inc. (NASDAQ:RGNX) in the second quarter, HoldingsChannel reports. The institutional investor purchased 20,379 shares of the biotechnology company’s stock, valued at approximately $238,000.

Several other institutional investors and hedge funds have also made changes to their positions in RGNX. PNC Financial Services Group Inc. lifted its stake in REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 746 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in REGENXBIO during the first quarter valued at $56,000. Headlands Technologies LLC boosted its holdings in REGENXBIO by 276.8% in the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,812 shares during the last quarter. Diversified Trust Co acquired a new stake in REGENXBIO during the 2nd quarter worth about $121,000. Finally, ProShare Advisors LLC grew its position in REGENXBIO by 8.3% during the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 874 shares during the period. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Stock Down 1.4 %

RGNX opened at $10.60 on Friday. The firm’s fifty day simple moving average is $11.38 and its two-hundred day simple moving average is $13.49. REGENXBIO Inc. has a 52-week low of $9.11 and a 52-week high of $28.80. The company has a market cap of $522.11 million, a price-to-earnings ratio of -1.80 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. The business had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $22.97 million. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.66) earnings per share. On average, research analysts forecast that REGENXBIO Inc. will post -4.66 EPS for the current year.

Insider Activity

In other REGENXBIO news, Director Kenneth T. Mills sold 12,221 shares of REGENXBIO stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $13.78, for a total value of $168,405.38. Following the sale, the director now owns 408,035 shares in the company, valued at $5,622,722.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Kenneth T. Mills sold 12,221 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total value of $168,405.38. Following the completion of the transaction, the director now owns 408,035 shares of the company’s stock, valued at approximately $5,622,722.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Curran Simpson sold 9,648 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $15.04, for a total value of $145,105.92. Following the sale, the chief executive officer now directly owns 170,137 shares in the company, valued at $2,558,860.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,069 shares of company stock worth $833,602 over the last ninety days. Corporate insiders own 13.13% of the company’s stock.

Wall Street Analysts Forecast Growth

RGNX has been the topic of a number of recent research reports. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of REGENXBIO in a research report on Wednesday, September 4th. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, Raymond James reissued an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average price target of $35.45.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.